Adverse effects of treatment · adults and children with cystic fibrosis and a positive microbiological isolate of MRSA from a respiratory tract specimen
Oral plus nebulised antibiotics showed no clear difference in adverse effects of treatment compared with oral antibiotics plus nebulised placebo (low certainty).
1 finding from 1 review
Time until next positive MRSA isolate (from clinically relevant respiratory culture) · adults or children with positive microbiological isolate of MRSA from a respiratory tract specimen
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life: CFRSD‐CRISS symptom score · adults or children with positive microbiological isolate of MRSA from a respiratory tract specimen
1 finding from 1 review
FEV1 % predicted: absolute change from baseline · adults or children with positive microbiological isolate of MRSA from a respiratory tract specimen
1 finding from 1 review
Change in weight (kg) · adults or children with positive microbiological isolate of MRSA from a respiratory tract specimen
1 finding from 1 review
Exacerbation frequency · adults or children with positive microbiological isolate of MRSA from a respiratory tract specimen
1 finding from 1 review
Adverse effects of treatment · adults or children with positive microbiological isolate of MRSA from a respiratory tract specimen
1 finding from 1 review
Eradication of MRSA · adults and children with cystic fibrosis and a positive microbiological isolate of MRSA from a respiratory tract specimen
Oral plus nebulised antibiotics showed no clear difference in eradication of MRSA compared with oral antibiotics plus nebulised placebo (low certainty).
1 finding from 1 review
Time until next positive MRSA isolate (from clinically relevant respiratory culture) · adults and children with cystic fibrosis and a positive microbiological isolate of MRSA from a respiratory tract specimen
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of participants experiencing an attacka · people with familial Mediterranean fever
Colchicine (oral) may leads to lower number of participants experiencing an attacka,b compared with placebo (low certainty).
1 finding from 1 review
Prevention of AA amyloidosis · people with familial Mediterranean fever
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse drug reactions · people with familial Mediterranean fever
1 finding from 1 review
Acute‐phase response · people with familial Mediterranean fever
1 finding from 1 review
Number of participants experiencing an attacka · people with familial Mediterranean fever
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Duration of attacks · people with familial Mediterranean fever
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time between attacks · people with familial Mediterranean fever
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Prevention of AA amyloidosis · people with familial Mediterranean fever
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse drug reactions · people with familial Mediterranean fever
1 finding from 1 review
Acute‐phase response · people with familial Mediterranean fever
1 finding from 1 review
Number of participants experiencing an attacka · people with familial Mediterranean fever
Anakinra showed no clear difference in number of participants experiencing an attacka compared with placebo (moderate certainty).
1 finding from 1 review